• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYBoard
  • MYInsights
  • Strategy & Consulting
  • Contact Us
Select Page

Boruzu Approved by FDA For Multiple Myeloma, Mantle Cell Lymphoma

by | Sep 6, 2024 | Uncategorized

Source: CureToday articles Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma. Read More

Moving Forward in Multiple Myeloma: Earlier Lines of CAR-T Cell Therapy

by | Sep 4, 2024 | Uncategorized

Source: CureToday articles Three years after the first FDA approval of CAR-T cell therapy, patients with multiple myeloma are starting to see the therapy emerge in earlier lines. Read More

Speeding Up With CAR-T Cell Therapy in Multiple Myeloma

by | Sep 3, 2024 | Uncategorized

Source: CureToday articles CAR-T cell therapy is moving to earlier lines of multiple myeloma treatment. Read More

Multiple Myeloma Remission: A Glimmer of Hope

by | Aug 30, 2024 | Uncategorized

Source: CureToday articles As soon as I entered complete remission for multiple myeloma, I felt a glimmer of hope. Read More

10 Multiple Myeloma Questions and Answers: Treatments and Side Effects

by | Aug 29, 2024 | Uncategorized

Source: CureToday articles Patients with multiple myeloma now have several available treatment options, so it’s important to have answers to some of the frequently asked questions. Read More

The Solitude of Reality With Multiple Myeloma

by | Aug 28, 2024 | Uncategorized

Source: CureToday articles I was diagnosed with stage 1 multiple myeloma in 2018 and writing poetry helped me work through feelings of anger and acceptance. Read More
« Older Entries
Next Entries »

Recent Content

  • Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma
  • IVIG Supplementation Reduces Infection Risk in Patients With Multiple Myeloma Receiving Teclistamab
  • Combination induces durable responses in advanced multiple myeloma
  • Patient-reported outcome domains in multiple myeloma randomized controlled trials and association with survival outcomes
  • Peroxiredoxin 6 maintains mitochondrial homeostasis and promotes tumor progression through ROS/JNK/p38 MAPK signaling pathway in multiple myeloma
  • Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial
  • Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
  • Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
  • A Year of Resilience: Looking Back After a Myeloma Diagnosis
  • Real-World Outcomes Show Efficacy, Safety of Ciltacabtagene Autoleucel in Relapsed, Refractory Multiple Myeloma
  • Facebook
  • X
  • Instagram
©2016-2024 MYELOMA360
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT